Their post hoc analysis suggests that patients with DM derived statistically significant benefit from DAPT in reducing END (5.2% vs 8.8%; adjusted risk difference, −4.1%; P = 0.04), whereas those without DM did not reach statistical significance (4.6% vs 6.1%; adjusted risk difference, −1.9%; P = 0.07).
← all excerpts
Dual antiplatelet therapy in acute ischemic stroke: Does diabetes mellitus define a target population?
1
0.0700
0.0700